Tokyo, October 11, 2025 — JSR Corporation (Minato-ku, Tokyo; Representative Director, CEO, and President: Tetsuro Hori; “JSR”) has concluded an agreement with OMRON Healthcare Corporation (Muko City, Kyoto Prefecture; President and CEO: Ayumu Okada; “OMRON Healthcare”) to transfer its long-term Holter ECG analysis service, Heartnote^®, to OMRON Healthcare. The transfer is scheduled to take effect on Thursday, January 1, 2026.

Summary of the Business Transfer:
　・Target: JSR’s Heartnote^® busines
　・Date of agreement: September 29, 2025
　・Scheduled transfer (closing) date: January 1, 2026

Launched in August 2020, the Heartnote^® business introduced Japan’s first service model using the world’s thinnest and lightest flexible patch-type device. As a pioneer in the field, it has detected more than 10,000 cases of atrial fibrillation, contributing to early detection and treatment.

OMRON Healthcare, which has been developing home-use electrocardiogram (ECG) devices and services and conducting educational activities on cardiac disease risks, will take over the expertise JSR has cultivated in ECG device technology and analysis accumulated through its Heartnote^® business. Building on this foundation, OMRON Healthcare aims to expand its ECG business in Japan from home monitoring to include diagnosis and treatment in medical institutions.

By creating a comprehensive business model that supports more patients and healthcare professionals, OMRON Healthcare will accelerate the realization of its business vision of “zero events” – zero incidence of cerebral and cardiovascular diseases.